Ion channels are fundamental regulators of T cell Ca2+ signaling and effector functions (Feske et al., 2015) and we have shown that treatment of HNSCC patients with pembrolizumab increases KCa3.1 and Kv1.3 activity in CD8+ PBTs (Newton et al., 2020). The gene discussed is KCNA3; the disease is head and neck squamous cell carcinoma.